JP2016510316A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016510316A5 JP2016510316A5 JP2015549801A JP2015549801A JP2016510316A5 JP 2016510316 A5 JP2016510316 A5 JP 2016510316A5 JP 2015549801 A JP2015549801 A JP 2015549801A JP 2015549801 A JP2015549801 A JP 2015549801A JP 2016510316 A5 JP2016510316 A5 JP 2016510316A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- compound
- subject
- tables
- mll
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 12
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 208000032839 leukemia Diseases 0.000 claims 6
- 102000004632 fms-Like Tyrosine Kinase 3 Human genes 0.000 claims 5
- 108010003374 fms-Like Tyrosine Kinase 3 Proteins 0.000 claims 5
- 102100039489 Histone-lysine N-methyltransferase, H3 lysine-79 specific Human genes 0.000 claims 4
- 102100021090 Homeobox protein Hox-A9 Human genes 0.000 claims 4
- 101000963360 Homo sapiens Histone-lysine N-methyltransferase, H3 lysine-79 specific Proteins 0.000 claims 4
- 101150029107 MEIS1 gene Proteins 0.000 claims 4
- 108700041619 Myeloid Ecotropic Viral Integration Site 1 Proteins 0.000 claims 4
- 102000047831 Myeloid Ecotropic Viral Integration Site 1 Human genes 0.000 claims 4
- 108010027263 homeobox protein HOXA9 Proteins 0.000 claims 4
- 208000024891 symptom Diseases 0.000 claims 4
- 230000005856 abnormality Effects 0.000 claims 3
- 210000000349 chromosome Anatomy 0.000 claims 3
- 230000002068 genetic effect Effects 0.000 claims 3
- 230000004927 fusion Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 230000008707 rearrangement Effects 0.000 claims 2
- SFHYNDMGZXWXBU-LIMNOBDPSA-N 6-amino-2-[[(e)-(3-formylphenyl)methylideneamino]carbamoylamino]-1,3-dioxobenzo[de]isoquinoline-5,8-disulfonic acid Chemical compound O=C1C(C2=3)=CC(S(O)(=O)=O)=CC=3C(N)=C(S(O)(=O)=O)C=C2C(=O)N1NC(=O)N\N=C\C1=CC=CC(C=O)=C1 SFHYNDMGZXWXBU-LIMNOBDPSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 210000004976 peripheral blood cell Anatomy 0.000 claims 1
- 210000002381 plasma Anatomy 0.000 claims 1
- 210000003296 saliva Anatomy 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 230000005945 translocation Effects 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261745294P | 2012-12-21 | 2012-12-21 | |
| US61/745,294 | 2012-12-21 | ||
| PCT/US2013/077082 WO2014100662A1 (en) | 2012-12-21 | 2013-12-20 | Dot1 l inhibitors for use in the treatment of leukemia |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018192426A Division JP2019031525A (ja) | 2012-12-21 | 2018-10-11 | 白血病の治療に使用するためのｄｏｔ１ｌ阻害剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016510316A JP2016510316A (ja) | 2016-04-07 |
| JP2016510316A5 true JP2016510316A5 (cg-RX-API-DMAC7.html) | 2017-02-02 |
Family
ID=49956460
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015549801A Pending JP2016510316A (ja) | 2012-12-21 | 2013-12-20 | 白血病の治療に使用するためのｄｏｔ１ｌ阻害剤 |
| JP2018192426A Pending JP2019031525A (ja) | 2012-12-21 | 2018-10-11 | 白血病の治療に使用するためのｄｏｔ１ｌ阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018192426A Pending JP2019031525A (ja) | 2012-12-21 | 2018-10-11 | 白血病の治療に使用するためのｄｏｔ１ｌ阻害剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20150342979A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2934550A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2016510316A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2013361076B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2894220A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014100662A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2882750A4 (en) | 2012-08-10 | 2016-08-17 | Epizyme Inc | INHIBITORS OF THE PROTEIN METHYLTRANSFERASE DOT1L AND METHOD OF USE THEREOF |
| US9597348B2 (en) | 2012-09-06 | 2017-03-21 | Epizyme, Inc. | Method of treating leukemia |
| US9446064B2 (en) | 2013-03-14 | 2016-09-20 | Epizyme, Inc. | Combination therapy for treating cancer |
| AU2014239520A1 (en) | 2013-03-15 | 2015-09-10 | Epizyme, Inc. | Methods of synthesizing substituted purine compounds |
| US20170166976A1 (en) * | 2014-07-18 | 2017-06-15 | The Regents Of The University Of Colorado, A Body Corporate | Dot1l inhibition in patients with mn1-high aml |
| WO2016023017A1 (en) * | 2014-08-08 | 2016-02-11 | Baylor College Of Medicine | Dot1l inhibitors and uses thereof |
| WO2016029127A1 (en) * | 2014-08-22 | 2016-02-25 | The Regents Of The University Of Colorado, A Body Corporate | Dot1l inhibitors and uses thereof |
| CA2960287A1 (en) * | 2014-09-17 | 2016-03-24 | Epizyme, Inc. | Injectable formulations for treating cancer |
| WO2016051396A1 (en) * | 2014-09-30 | 2016-04-07 | Susan Eve Vecht-Lifshitz | Pharmaceutical compositions for treating ebola virus disease |
| GB201519573D0 (en) | 2015-11-05 | 2015-12-23 | King S College London | Combination |
| US10869868B2 (en) | 2016-01-26 | 2020-12-22 | Memorial Sloan Kettering Cancer Center | Targeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemia |
| CN110691779B (zh) | 2017-03-24 | 2023-10-10 | 库拉肿瘤学公司 | 治疗血液系统恶性肿瘤和尤因肉瘤的方法 |
| GB201901817D0 (en) | 2019-02-11 | 2019-04-03 | Phoremost Ltd | Methods |
| CN110092804A (zh) * | 2019-03-29 | 2019-08-06 | 广州盈升生物科技有限公司 | 一种含双环基团的嘌呤化合物及其制备方法 |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025080946A2 (en) | 2023-10-12 | 2025-04-17 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2008041767A1 (ja) * | 2006-10-05 | 2010-02-04 | 萬有製薬株式会社 | ＡｕｒｏｒａＡ阻害剤の薬効を予測又は診断する遺伝子・タンパク質マーカー |
| CA2598893C (en) * | 2006-10-11 | 2012-04-10 | Astellas Pharma Inc. | Eml4-alk fusion gene |
| JP2010046057A (ja) * | 2008-07-22 | 2010-03-04 | Akita Univ | 癌細胞の治療感受性増強剤、癌細胞の治療感受性の判定方法、および癌細胞の治療感受性判定キット |
| HRP20160655T1 (hr) * | 2010-12-03 | 2016-09-23 | Epizyme, Inc. | Supstituirani spojevi purina i 7-deazapurina kao modulatori epigenetskih enzima |
| US9597348B2 (en) * | 2012-09-06 | 2017-03-21 | Epizyme, Inc. | Method of treating leukemia |
| US9446064B2 (en) * | 2013-03-14 | 2016-09-20 | Epizyme, Inc. | Combination therapy for treating cancer |
| US10143704B2 (en) * | 2013-11-13 | 2018-12-04 | Epizyme, Inc. | Methods for treating cancer |
-
2013
- 2013-12-20 US US14/654,125 patent/US20150342979A1/en not_active Abandoned
- 2013-12-20 AU AU2013361076A patent/AU2013361076B2/en not_active Ceased
- 2013-12-20 WO PCT/US2013/077082 patent/WO2014100662A1/en not_active Ceased
- 2013-12-20 CA CA2894220A patent/CA2894220A1/en not_active Abandoned
- 2013-12-20 EP EP13821345.9A patent/EP2934550A1/en not_active Withdrawn
- 2013-12-20 JP JP2015549801A patent/JP2016510316A/ja active Pending
-
2018
- 2018-10-11 JP JP2018192426A patent/JP2019031525A/ja active Pending
-
2019
- 2019-09-19 US US16/575,957 patent/US20200113923A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016510316A5 (cg-RX-API-DMAC7.html) | ||
| Dai et al. | The potential role of necroptosis in clinical diseases | |
| Ghiaur et al. | Mechanisms of resistance to FLT3 inhibitors and the role of the bone marrow microenvironment | |
| Showel et al. | Advances in treating acute myeloid leukemia | |
| Tirro et al. | Molecular alterations in thyroid cancer: from bench to clinical practice | |
| Follini et al. | Strategies to overcome resistance mechanisms in T-cell acute lymphoblastic leukemia | |
| Badura et al. | Differential effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway in acute lymphoblastic leukemia | |
| Paoluzzi et al. | Response to anti-PD1 therapy with nivolumab in metastatic sarcomas | |
| Fransecky et al. | Outlook on PI3K/AKT/mTOR inhibition in acute leukemia | |
| Thielen et al. | Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: A randomised trial of the Dutch–Belgian Cooperative Trial for Haemato-Oncology (HOVON) | |
| Stanley et al. | Recent advances in understanding clonal haematopoiesis in aplastic anaemia | |
| Rizzo et al. | Defining the genomic landscape of head and neck cancers through next‐generation sequencing | |
| JP2009507918A5 (cg-RX-API-DMAC7.html) | ||
| JP2017503481A5 (cg-RX-API-DMAC7.html) | ||
| Andrisani | Epigenetic mechanisms in hepatitis B virus-associated hepatocellular carcinoma | |
| Choi et al. | Leukemic stem cells and hematological malignancies | |
| An et al. | Loss of Cbl and Cbl-b ubiquitin ligases abrogates hematopoietic stem cell quiescence and sensitizes leukemic disease to chemotherapy | |
| Klonou et al. | Molecular basis of pediatric brain tumors | |
| Wang et al. | RET fusion in advanced non-small-cell lung cancer and response to cabozantinib: a case report | |
| Fiorino et al. | Integrated antitumor activities of cellular immunotherapy with CIK lymphocytes and interferons against KIT/PDGFRA wild type GIST | |
| Stankovic Stojanovic et al. | Chronic myeloid leukaemia and sickle cell disease: could imatinib prevent vaso-occlusive crisis? | |
| Arslan et al. | Neutropenia and thrombocytopenia induced by quetiapine monotherapy: a case report and review of literature | |
| Bibi et al. | Tyrosine kinase inhibition in mastocytosis: KIT and beyond KIT | |
| Ishfaq et al. | Molecular characterization of FLT3 mutations in acute leukemia patients | |
| Botrous et al. | Artemisinin pre-treatment fore cisplatin dosage enhances high grade urothelial carcinoma treatment in male albino mice via reverse gene expression modulation of FGFR3, HRAS, P53 and KDM6A |